These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24458801)

  • 1. The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery.
    Kouvelos GN; Arnaoutoglou EM; Milionis HJ; Raikou VD; Papa N; Matsagkas MI
    Angiology; 2015 Feb; 66(2):128-35. PubMed ID: 24458801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study.
    Kouvelos GN; Arnaoutoglou EM; Matsagkas MI; Kostara C; Gartzonika C; Bairaktari ET; Milionis HJ
    J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):5-12. PubMed ID: 22573476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
    Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
    J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
    Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
    Yamazaki D; Ishida M; Watanabe H; Nobori K; Oguma Y; Terata Y; Koyama T; Iino K; Kosaka T; Ito H
    Lipids Health Dis; 2013 Feb; 12():9. PubMed ID: 23374898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
    Torimoto K; Okada Y; Mori H; Hajime M; Tanaka K; Kurozumi A; Narisawa M; Yamamoto S; Arao T; Matsuoka H; Inokuchi N; Tanaka Y
    Lipids Health Dis; 2013 Sep; 12():137. PubMed ID: 24053480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
    Briseño GG; Mino-León D
    Curr Med Res Opin; 2010 May; 26(5):1075-81. PubMed ID: 20225991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
    Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M
    Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
    Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Oct; 22(10):2037-9. PubMed ID: 17022863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE; Miltersteiner DR; Campos BM
    J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.